COMP <GO>
RMD vs ABBV // EV/EBITDA & P/E VALUATION
ResMed Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: RMD 9
— ABBV 6
▲ EV/EBITDA & P/E VALUATION LEADER: RMD
LAST: $229.94 (-9.05%) • MKT CAP: $35.56B
valuation
19.9x
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
valuation
33.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RMD VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RMD | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.40% | 70.20% | -10.80 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 22.90% | 29.00% | -6.10 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 19.9x | 33.3x | -13.40 | RMD | /valuation <GO> |
| Free Cash Flow Yield | 4.67% | 3.47% | +1.20 | RMD | /fcf-yield <GO> |
| Operating Margin | 32.70% | 24.60% | +8.10 | RMD | /operating-margins <GO> |
| Net Profit Margin | 27.20% | 6.90% | +20.30 | RMD | /net-margins <GO> |
| Revenue Growth (YoY) | 9.80% | 8.60% | +1.20 | RMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.87% | 2.27% | -1.40 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.49 | 5.33 | +7.16 | RMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | RMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 7.40% | -0.70 | RMD | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.8 | 72.8 | -31.02 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.93 | 1.15 | -0.22 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.6x | 113.1x | -89.50 | RMD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $35.56B | $513.86B | -$478.30B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RMD REV | ABBV REV | RMD GROSS % | ABBV GROSS % | RMD FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.15B | $61.16B | 59.4% | 70.2% | $1.66B | $17.82B |
| FY 2024 | $4.69B | $56.33B | 56.7% | 70.0% | $1.30B | $17.83B |
| FY 2023 | $4.22B | $54.32B | 44.0% | 44.0% | $503.3M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RMD // BETA 0.93
ABBV // BETA 1.15